Vertex updated data on diabetes candidate VX-880 encouraging
Updated data from Vertex Pharmaceuticals (NASDAQ:VRTX) type 1 diabetes candidate VX-880 indicated that reductions in HbA1c were seen in all patients on the stem cell-derived therapy.
At 90 days, all patients on treatment demonstrated improved time-in-range on continuous insulin monitoring, and reduction or elimination of exogenous insulin use.

The data on the insulin-producing islet cell therapy was presented at a medical conference in Europe.
Two patients have at least 12-months of follow-up following infusion. The first patient achieved insulin independence at day 270 through month 24. The second patient achieved insulin independence at day 180 through month 12.


More on Vertex Pharmaceuticals

A Total Return Superstar: Vertex Pharmaceuticals
Vertex Pharmaceuticals: Critical Period For The Pipeline Is Approaching
Vertex appoints Atkinson EVP Chief Technical Operations Officer
Bluebird bio favored at Baird as sickle cell disease space gets busy